FDA decision: Lorundrostat by Mineralys Therapeutics (on or before December 22, 2026)Yes87%No21%$75 volView details
FDA decision: Tozorakimab by AstraZeneca (on or before March 31, 2027)Yes85%No24%$434 volView details
FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)Yes89%No12%$4,230 volView details